Gynecologic Cancers

Latest News


CME Content


This survey is open to any woman diagnosed with ovarian, fallopian tube, or primary peritoneal cancer, regardless of whether or not you have had genetic counseling or testing.

Genetic counseling before BRCA genetic testing improves patient knowledge, understanding, and satisfaction. However, a new analysis has found that most women undergoing BRCA genetic testing did not receive counseling prior to testing, despite national guidelines and recommendations.

From Vision To Legacy

By

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer and ovarian cancer.

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib (Lynparza) in the treatment of women with ovarian cancer, Ursula A. Matulonis, MD, explained during a plenary session at the 2015 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.

Treatment with bevacizumab (Avastin) plus chemotherapy resulted in a non-statistically significant improvement in overall survival (OS) of nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.